Connect2Innovate Special Part 2 - Liquid Biopsy
Connect2Innovate Special Part 1 - Biosensing & Interfaces
Over the past few decades, professionals in the life science industry have been creating innovative ways to diagnose and test diseases efficiently. One of them is liquid biopsies – a method of obtaining blood, urine or cerebrospinal fluid to detect cancer cells – which can be used to predict a variety of diseases by identifying specific biomarkers .
This non-invasive technique is much more efficient compared with a standard method called tissue biopsy . The future of liquid biopsies is in an advancing field, which has been applied in the relevant healthcare areas. However, despite its excellent design in diagnostics, it comes with its own unique challenges. These challenges include sensitivity issues preventing the method to become a standard test . There is hope that the advancement of therapeutic technologies can improve this tool. Liquid biopsy technologies will play an important and evolving role in the future of diagnosis and care for patients.
RNA interference is hitting the market - Alnylam’s success heralds a new era for RNAi therapeutics
The Science Entrepreneur Club has partnered up with Merck Accelerator and Clustermarket to support innovative startups who build technologies across the areas of Biosensing & Interfaces, Clean Meat and Liquid Biopsy Technologies. With the overall theme of ‘Connect2Innovate’, we are organising a series of events: three meetups on each of the key areas, and a pitching event, which will provide the opportunity to win a cash prize and Sigma Aldrich vouchers for laboratory supplies. The winner also receives a ‘Golden Ticket’ to the Merck Accelerator Selection Days taking place in November with the opportunity to join the Merck Accelerator at the Innovation Centre in Darmstadt, Germany in January 2020.
Health Technology - The Digital Revolution: Part 2 Digitising Diabetes
It has been a bumpy ride for RNA interference-based therapeutics. The protein-silencing phenomenon that shot into the spotlight with its 2006 Nobel Prize fell (aptly) quiet thereafter, suffering clinical disappointments and losing high-profile backing. But it is back with a bang: the first RNAi drug was FDA approved in August and a number of Big Pharma companies are striking deals with developers. Does this mark a watershed moment for RNAi therapeutics?
Health Technology: The Digital Revolution - Part 1: AI & Imaging
Technological advances are permeating into the healthcare industry and are transforming the norns of patient care. The development of medical technology (MedTech) devices that can be used by clinicians, nurses, technicians and, most importantly, patients themselves is rapidly increasing. Such technologies are enabling greater access to patient data to monitor disease status and predict future health events. With tech giants such as Google and Apple diving into healthcare, only further acceleration of these patient-centred technologies can be expected, unlocking a wealth of patient data. Not only this, but the rise of wearables and mobile technologies has expedited the mass collation of health data.
Clustermarket Taps In To GE Healthcare Life Sciences Customers To Reach UK Innovators
Our era is witnessing a technological revolution. Healthcare is becoming increasingly digitised, empowering both patient and physician. We’re using computational power and data to better predict, diagnose and manage patients with complex health conditions. In part one of this series we explore AI and imaging and the effects these have on the diagnosis and treatment of cancer.
Clustermarket, the leading UK online scientific equipment sharing and booking platform, has enlisted the support of GE Healthcare’s Life Sciences business in an agreement aimed at helping innovators in the UK access specialized life sciences and biotech equipment.